Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,127.31 -11.95 -0.38%
FTSE 100 6,560.77 -23.40 -0.36%
DAX 9,300.44 -17.38 -0.19%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

Star Scientific Announces Patent Claims to Anatabine Citrate to be Granted by PTO



Star Scientific Announces Patent Claims to Anatabine Citrate to be Granted by
                                     PTO

PR Newswire

GLEN ALLEN, Va., Sept. 12, 2013

GLEN ALLEN, Va., Sept. 12, 2013 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ:
STSI) announced that the U.S. Patent and Trademark Office ("PTO") issued a
Notice of Allowance on September 3, 2013 to Rock Creek Pharmaceuticals, Inc.,
its wholly owned subsidiary, in Application No. 13,477,295, covering anatabine
citrate, the active component in the company's Anatabloc® products. A Notice
of Allowance, issued by the PTO, is a notification that an applicant is
entitled to a patent.  The patent is expected to issue within approximately
two months. 

(Logo:  http://photos.prnewswire.com/prnh/20130319/PH79245LOGO )

The allowed '295 application discloses an improved process for synthesizing
anatabine that facilitates larger scale, commercial production, as well as
novel salts of anatabine including anatabine citrate. An initial patent, U.S.
Patent No. 8,207,346, based on the same disclosure, was awarded on June 26,
2012 and covered claims for the improved process for synthesizing anatabine. 
The claims allowed in the '295 application cover anatabine citrate per se as
well as formulations containing anatabine citrate. The company, through Rock
Creek, continues to pursue several additional patent applications covering
dietary formulations containing anatabine, and methods of administering
anatabine for the nutritional management of disorders associated with
unhealthy levels of inflammation.

Certain statements contained in this release constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. Such statements include, but are not limited to statements identified
by words such as "believes," "expects," "anticipates," "estimates," "intends,"
"plans," "targets," "projects" and similar expressions. The statements in this
release are based upon the current beliefs and expectations of our company's
management and are subject to significant risks and uncertainties. Actual
results may differ from those set forth in the forward-looking statements.
Numerous factors could cause or contribute to such differences, including, but
not limited to, results of clinical trials and/or other studies, the
challenges inherent in new product development initiatives, including the
continued development and market acceptance of our nutraceutical dietary
supplements products, the effect of any competitive products, our ability to
license and protect our intellectual property, our ability to raise additional
capital in the future that is necessary to maintain our business, changes in
government policy and/or regulation, potential litigation by or against us,
any governmental review of our products or practices and the outcome of the
ongoing investigations as well as other risks discussed from time to time in
our filings with the Securities and Exchange Commission, including, without
limitation, our annual report on Form 10-K and 10K/A for the fiscal year ended
December 31, 2012 and our quarterly reports on Form 10-Q for the quarters
ended March 31, 2013 and June 30, 2013. We undertake no duty to update any
forward-looking statement or any information contained in this press release
or in other public disclosures at any time.

About Star Scientific
Star Scientific, Inc. is a technology-oriented company with a mission to
promote maintenance of a healthy metabolism and lifestyle. Through its wholly
owned subsidiary, Rock Creek Pharmaceuticals, Star Scientific has been engaged
in the manufacturing, sale, and marketing of two nutraceutical dietary
supplements, a cosmetic facial cream and facial serum, as well as the
development of other nutraceuticals and pharmaceuticals. The company also
continues to pursue the licensing of the technology behind its proprietary
StarCured® curing process and its related products. Rock Creek Pharmaceuticals
has scientific and research offices in Gloucester, MA, and a regulatory office
in Washington, DC. Star Scientific has a Corporate and Sales Office in Glen
Allen, VA, and an Executive, Scientific & Regulatory Affairs office in
Washington, DC.

Contact:
Talhia T. Tuck
Vice President, Communications and Investor Relations
Star Scientific, Inc.
(202)887-5100
ttuck@starscientific.com

SOURCE Star Scientific, Inc.

Website: http://www.starscientific.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement